Find Clinical Trial

Effects of oral chronic administration of ivabradine (7.5 mg bid) in comparison to placebo (bid) on top of beta-blockers, on central aortic blood pressure. Randomized, cross-over, double blind, multicentre, study over 10 weeks in patients with stable coronary artery disease, type II diabetes and a resting heart rate equal or superior to 70 bpm, already treated with beta-blockers.


← Back
Study Phase

Phase 2

Therapeutic Area

Cardiovascular Diseases

Active substance/
Medical device

S016257, IVABRADINE

SponsorInstitut de Recherches Internationales Servier (I.R.I.S)
Active Substance CodeS016257
Protocol CodeCL2-16257-096
EudraCT Code2011-004779-35


Documents and links

Results summary READ MORE




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2017 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
More information

Report a side-effect with a drug.
Accessibility